Core Viewpoint - Xianju Pharmaceutical announced a one-year extension for its fundraising project "High-end Formulation Internationalization Construction Project" while maintaining the project’s implementation subject, location, funding purpose, and investment scale unchanged [1][2] Group 1: Project Details - The total committed investment amount for the "High-end Formulation Internationalization Construction Project" is 700 million yuan, with 636 million yuan already invested as of October 31, 2025, representing a progress of 90.79% [1] - The remaining funds will be used for civil construction, cleanroom facilities, equipment warranty payments, and supporting testing facilities required for the formal production phase of certain products [1] - The project’s main buildings have completed construction and received acceptance reports for environmental protection, fire safety, and safety inspections [1] Group 2: Reasons for Delay - The project’s timeline has been extended from December 31, 2025, to December 31, 2026, due to pending approvals for some declared products and the production lines not yet being officially operational [2] - The company aims to strategically position itself for capacity expansion in high-end formulation international products, which involves establishing a new formulation technology platform [2] - The nature of pharmaceutical research, characterized by long cycles, multiple stages, and high technical difficulty, contributes to the uncertainty in the approval timeline for product formulations [2] Group 3: Financial Performance - Xianju Pharmaceutical has faced declining performance, with revenue and net profit both decreasing for two consecutive years in 2023 and 2024 [3] - For the first three quarters of this year, the company reported revenue of 2.826 billion yuan, a year-on-year decrease of 12.71%, and a net profit attributable to shareholders of 407 million yuan, down 23.29% year-on-year [3] Group 4: Regulatory Issues - In September, the company and its chairman received warning letters due to violations related to the misuse of raised funds, including not following proper review procedures and using raised funds for unrelated expenses [4] - The Zhejiang Securities Regulatory Bureau held the chairman and other executives responsible for these violations and decided to implement supervisory measures, including warning letters [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 √ 是 □ 否 √ 是 □ 否 如否，请详细说明：______________________________ 十五、被提名人具备上市公司运作相关的基本知识，熟悉相关法律、行政法规、部门规章、规范性文件 及深圳证券交易所业务规则，具有五年以上法律、经济、管理、会计、财务或者其他履行独立董事职责 所必需的工作经验。 √ 是 □ 否 如否，请详细说明：______________________________ 十六、以会计专业人士被提名的，被提名人至少具备注册会计师资格，或具有会计、审计或者财务管理 专业的高级职称、副教授或以上职称、博士学位，或具有经济管理方面高级职称且在会计、审计或者财 务管理等专业岗位有五年以上全职工作经验。 □ 是 □ 否 √ 不适用 如否，请详细说明：______________________________ 十七、被提名人及其直系亲属、主要社会关系均不在公司及其附属企业任职。 如否，请详细说明：______________________________ 十四、被提名人担任独立董事不会违反其他法律、行政法规、部门规章、规范性文件和深 ...